newsfilter
← Latest News
Business Wire·

Better Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes

Submission follows completion of first-in-class trial demonstrating significant improvements in A1c reduction with investigational therapy targeting the root causes of type 2 diabetes. Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital t